PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Key Laboratory of Glucolipid Metabolic Diseases of The Ministry of Education, Guangzhou, China; Guangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University, Guangzhou, China.\', \'The First Affiliated Hospital/School of Clinical Medicine, Guangdong Pharmaceutical University, Guangzhou, China.\', \'Key Laboratory of Glucolipid Metabolic Diseases of The Ministry of Education, Guangzhou, China; Guangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University, Guangzhou, China. Electronic address: deweiye@gdpu.edu.cn.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0753-3322(21)00467-410.1016/j.biopha.2021.111685
?:hasPublicationType
?:journal
  • Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
is ?:pmid of
?:pmid
?:pmid
  • 34015585
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • COVID-19 and metabolic comorbidities: An update on emerging evidences for optimal therapies.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all